Beyond excited to present our study on the glycine transporter #GlyT2, a promising #non-opioid target for the treatment of neuropathic pain.
@biorxivpreprint.bsky.social
www.biorxiv.org/content/10.1...
Chronic neuropathic pain, caused by nerve damage or disease, affects 10% of the population with rising incidence. The burden is exacerbated by ineffective treatments and overreliance on opioids. Neuro...
